Mabwell(SH:688062) Xin Lang Cai Jing·2025-10-23 02:13Group 1 - The core point of the news is that Maiwei Biotech's stock price has dropped by 5.29%, currently trading at 42.29 CNY per share, with a total market capitalization of 16.899 billion CNY [1] - Maiwei Biotech, established on May 12, 2017, and listed on January 18, 2022, focuses on the research, production, and sales of therapeutic biological products, with 99.91% of its revenue coming from product sales [1] - The trading volume for Maiwei Biotech reached 128 million CNY, with a turnover rate of 1.46% [1] Group 2 - Huafu Fund has a significant holding in Maiwei Biotech, with its Huafu Health and Entertainment Flexible Allocation Mixed A Fund (001563) holding 170,000 shares, accounting for 6.49% of the fund's net value [2] - The fund has experienced a floating loss of approximately 401,200 CNY today, despite having a year-to-date return of 43.71% [2] - The fund manager, Liao Qingyang, has been in position for nearly 4 years, with the fund's total asset size currently at 74.027 million CNY [2]